Advertisement

Topics

Allogene Therapeutics, Inc. Company Profile

10:39 EST 23rd January 2019 | BioPortfolio

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients.


News Articles [706 Associated News Articles listed on BioPortfolio]

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive...

IPO Roundup: Allogene IPO prices above high end of range, Livent pricing comes up short, while Audentes Therapeutics debuts

Allogene Therapeutics Inc raised $288 million by offering 18.4 million shares, putting a spotlight on the biotech IPO boom this year

Allogene Therapeutics Eyes IPO of up to $288 Million

Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public off...

Allogene files for IPO

Immuno-oncology firm Allogene Therapeutics Inc. filed for its initial public offering and plans to trade on the Nasdaq.

Allogene pulls in $120M to develop next-gen CAR-T therapies

Allogene Therapeutics raised $120 million through private financing, which it intends to use in developing allogeneic chimeri -More- 

Allogene’s IPO Raises $288M for Tests of “Off-the-Shelf” Cell Therapy

Allogene Therapeutics has raised $288 million in an IPO, marking one of the biggest stock market debuts for a biotech this year. The cell therapy developer sold 18.4 million shares at $18 apiece, with...

Focused on Off-the-Shelf CAR-T, Allogene Therapeutics Hits the Nasdaq at $18 Per Share

Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sal...

Allogene Therapeutics Announces the Formation of its Scientific Advisory Board

Allogene Therapeutics announced the implementation of its Scientific Advisory Board (SAB). The SAB is made up of five leaders in oncology, immunology, drug discovery and development, and will consult ...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [Kastle Therapeutics, LLC]

NA

Olopatadine hydrochloride [Somerset Therapeutics, LLC]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [Breathe Easy Therapeutics, Inc]

NA

Diclofenac sodium delayed release [Cambridge Therapeutics Technologies, LLC]

Diclofenac Sodium

Olopatadine hydrochloride [A-S Medication Solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [470 Associated PubMed Articles listed on BioPortfolio]

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Clinical Trials [169 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1292 Associated Companies listed on BioPortfolio]

Allogene Therapeutics, Inc.

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Allogene Therapeutics, Inc." on BioPortfolio

We have published hundreds of Allogene Therapeutics, Inc. news stories on BioPortfolio along with dozens of Allogene Therapeutics, Inc. Clinical Trials and PubMed Articles about Allogene Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Allogene Therapeutics, Inc. Companies in our database. You can also find out about relevant Allogene Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record